BRUCE SCHMIDT

President and Chief Executive Officer (Interim)

JACOB J. CLEMENT, Ph.D.

Senior Vice President, Science & Technology and Chief Science Officer

Dr. Clement joined MIGENIX in August 2002. In his role, Dr. Clement leads the R&D function at MIGENIX, with a focus on accelerating research and preclinical development, and expanding the Company's pipeline. Dr. Clement has been a leader in pharmaceutical research and development for over two decades. He brings considerable biotechnology and pharmaceutical experience to MIGENIX, having held executive and senior management positions at Abbott Laboratories, Scriptgen Pharmaceuticals, and Essential Therapeutics. Dr. Clement is widely published and has contributed to, and/or led, the development and approval of several drugs in anti-infectives and oncology. Dr. Clement has a Ph.D. and a MSPH from the University of North Carolina, an MS degree from Roosevelt University, and a B.A. degree from St. Mary’s University.

WILLIAM D. MILLIGAN, B.Sc.

Senior Vice President, Corporate Development and Chief Business Officer
Mr. Milligan joined MIGENIX in April 2002. Prior to joining MIGENIX, Mr. Milligan was President and CEO of Cytran Inc., a private biotechnology company based in Seattle, WA and prior to that, he was Chief Executive Officer of Intellivax International Inc., a private biotechnology company based in Montreal, Quebec and Baltimore, Maryland. Before leading Intellivax, he served eight years with Hoffmann-La Roche Ltd. (Canada) where he held various executive positions, including VP, Business Development and New Product Planning, VP, Sales Division, Pharmaceuticals and VP Biomedical Division. Prior to joining Hoffmann-LaRoche, he progressed through various marketing and sales management positions over eight years with Eli Lilly Canada Inc. During his career, Mr. Milligan has been responsible for the launch/commercialization of Axid, Prozac, Mobiflex, Soriatane, Hivid, Roferon-A, CellCept, Invirase, Cytovene, Manerix and Inhibace. Mr. Milligan holds a B.Sc. in Biology from the University of Calgary.

ARTHUR J. AYRES, CA

Senior Vice President, Finance and Chief Financial Officer
Mr. Ayres joined MIGENIX in November 1994 as Controller. He was appointed Director of Finance in January 2000, Vice President Finance and Chief Financial Officer in April 2001 and Senior Vice President Finance and Chief Financial Officer on June 15, 2005. Mr. Ayres also served as the Company's Secretary from January 9, 1995 to September 23, 1997. Mr. Ayres is a Chartered Accountant (1985) and has a B.A. (Hon.) in Commerce and Computer Science (1981) from Simon Fraser University. He has over 20 years of management, finance and related experience.

ANNKATRIN PETERSEN-JAPPELLI, M.D., M.A.

Vice President, Clinical Development

Dr. Petersen joined MIGENIX in May 2006 to lead the clinical development team. Prior to joining MIGENIX, Dr. Petersen was the Clinical Development Leader and Strategist, Medical Sciences, for Hepatitis C and several other exploratory antiviral compounds at Pfizer Inc. In this role, she was also a member of the in-licensing due diligence team for anti-infectives. Dr. Petersen joined Agouron Pharmaceuticals, Inc (acquired by Pfizer in 2000) in 1996 to become Director of International Clinical Development and Infectious Diseases. At Agouron/Pfizer she was responsible for the Phase I – IV clinical development of Viracept (nelfinavir mesylate) for the treatment of HIV infection, including filing the NDA and subsequent sNDAs for alternative dosing and pediatric indications. Prior to joining Agouron/Pfizer Dr. Petersen spent close to a decade with other leading international biotechnology and pharmaceutical companies including Sandoz (Novartis) in Switzerland, and Cytel in California. She has been responsible for managing the clinical development for several NDA-enabled programs at these companies, including Sandimmune (cyclosporine) for Rheumatoid Arthritis and Psoriasis. She received a Master of Economics (1978) and her M.D. degree (1985) from the Université of Lausanne in Switzerland and spent several years working in Internal Medicine before joining the pharmaceutical industry.

K. DAVID CAMPAGNARI, MBA

Vice President, Operations
Mr. Campagnari joined MIGENIX in June 2002. Prior to joining MIGENIX, he was Vice President of Operations at GenSci Orthobiologics of Irvine, CA. Before joining GenSci, Mr. Campagnari held several management positions at the American Red Cross, including General Manager of the Western Region (which included directing the processing of cardiovascular products) and Director, Quality and Regulatory Assessment at ARC National Headquarters. Mr. Campagnari holds a B.B.A. in Health Services Management and a MBA from National University in San Diego, CA.

C. ROBERT CORY, Ph.D., MBA

Vice President, Business Development
Dr. Cory joined MIGENIX in May 1995 as Manager, Business Development. He was appointed Director, Business Development in November 1998 and Vice President, Business Development in April 2001. Dr. Cory leads the Company's activities in sourcing and negotiating strategic alliances with industry partners and in-licensing and acquisition of technologies and product opportunities. Dr. Cory holds an MBA specializing in finance and strategic planning from the Wilfrid Laurier University School of Business and Economics. He received his doctorate from the University of Waterloo and did his post-doctoral training at the Ontario Veterinary College.